INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKTNEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
RCKT Investors With Large Losses are Encouraged to Contact Robbins LLP for Information About the Securities Class Action Filed Against Rocket Pharmaceuticals, Inc.SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (
NASDAQ: RCKT) securities between February 7, 2025 and May 26, 2025. Rocket is a fully integrated, late-stage biotechnology company focused on the development of gene therapies, with direct on-target mechanism of action and clear clinical endpoints, for rare and devastating diseases.
Deadline Alert: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”).
Deadline Approaching: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”).
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit And Upcoming Deadlines - RCKTNEW YORK CITY, NY / ACCESS Newswire / June 26, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) ShareholdersNEW YORK - June 26, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ: RCKT) of a class action securities lawsuit.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) ShareholdersSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKTNEW YORK CITY, NY / ACCESS Newswire / June 25, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) ShareholdersSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) ShareholdersNEW YORK - June 25, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ: RCKT) of a class action securities lawsuit.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors To Inquire About Securities Fraud Class Action
Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”). Rocket investors have until August 11, 2025 to file a lead plaintiff motion.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket PharmaceuticalsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit And Upcoming Deadlines - RCKTNEW YORK CITY, NY / ACCESS Newswire / June 24, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
Law Offices of Frank R. Cruz Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors To Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”). Rocket investors have until August 11, 2025 to file a lead plaintiff motion.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKTNEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Law Offices of Howard G. Smith Encourages Rocket Pharmaceuticals, Inc. (RCKT) Investors To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the “Class Period”). Rocket investors have until August 11, 2025 to file a lead plaintiff motion.
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming DeadlineNEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
